MX2012002702A - Vacuna de herpesvirus bovino. - Google Patents

Vacuna de herpesvirus bovino.

Info

Publication number
MX2012002702A
MX2012002702A MX2012002702A MX2012002702A MX2012002702A MX 2012002702 A MX2012002702 A MX 2012002702A MX 2012002702 A MX2012002702 A MX 2012002702A MX 2012002702 A MX2012002702 A MX 2012002702A MX 2012002702 A MX2012002702 A MX 2012002702A
Authority
MX
Mexico
Prior art keywords
bovine herpesvirus
viruses
mutant bovine
genomes
mutant
Prior art date
Application number
MX2012002702A
Other languages
English (en)
Inventor
Alain Francis Claude Vanderplasschen
Muriel Michele Chantal Thirion
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2012002702A publication Critical patent/MX2012002702A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16461—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a genomas mutantes del herpesvirus bovino de tipo 4, herpesvirus bovino de tipo 4 mutante; a genomas y virus mutantes del herpesvirus bovino de tipo 4 que llevan una secuencia de ADN heterólogo; células transfectadas con genomas mutantes del herpesvirus bovino de tipo 4; células infectadas con herpesvirus bovino de tipo 4 mutante; vacunas y vacunas portadoras que comprenden dicho herpesvirus bovino de tipo 4 mutante; métodos para preparar dichos genomas mutantes del herpesvirus bovino de tipo 4 y dicho herpesvirus bovino de tipo 4 mutante; y a kits de pruebas diagnósticas.
MX2012002702A 2009-09-03 2010-09-02 Vacuna de herpesvirus bovino. MX2012002702A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09169358 2009-09-03
US23989409P 2009-09-04 2009-09-04
PCT/EP2010/062846 WO2011026882A1 (en) 2009-09-03 2010-09-02 Bovine herpesvirus vaccine

Publications (1)

Publication Number Publication Date
MX2012002702A true MX2012002702A (es) 2012-03-21

Family

ID=42340855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002702A MX2012002702A (es) 2009-09-03 2010-09-02 Vacuna de herpesvirus bovino.

Country Status (8)

Country Link
US (1) US20120164169A1 (es)
EP (1) EP2473599B1 (es)
AU (1) AU2010291270B2 (es)
BR (1) BR112012004847B1 (es)
ES (1) ES2699828T3 (es)
MX (1) MX2012002702A (es)
WO (1) WO2011026882A1 (es)
ZA (1) ZA201201387B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9965472B2 (en) * 2012-08-09 2018-05-08 International Business Machines Corporation Content revision using question and answer generation
CN113061581A (zh) * 2021-03-22 2021-07-02 华中农业大学 一种山羊源牛疱疹病毒1型毒株及其应用
CN116042536B (zh) * 2022-08-02 2023-12-29 南京农业大学 一种牛疱疹病毒4型毒株及其培养方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948676A (en) * 1996-10-10 1999-09-07 The Trustees Of Columbia University In The City Of New York Immediate early protein from Kaposi's sarcoma-associated herpesvirus, DNA encoding same and uses thereof
US6322792B1 (en) * 1998-11-19 2001-11-27 Elliott D. Kieff Rhadino virus LANA acts in trans on a unit of rhadino virus DNA to mediate efficient episome persistance
US6482587B1 (en) * 1999-10-01 2002-11-19 The Regents Of The University Of Michigan Methods to inhibit or enhance the binding of viral DNA to genomic host DNA
US20110123485A1 (en) * 2007-03-27 2011-05-26 President And Fellows Of Harvard College Viral vectors for delivering vaccines for hiv and other infectious diseases
US20110110892A1 (en) * 2008-03-24 2011-05-12 President And Fellows Of Harvard College Vectors for delivering disease neutralizing agents
GB0810912D0 (en) * 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
WO2011134669A1 (en) * 2010-04-30 2011-11-03 Telormedix Sa Methods for inducing an immune response

Also Published As

Publication number Publication date
EP2473599B1 (en) 2018-10-17
US20120164169A1 (en) 2012-06-28
ES2699828T3 (es) 2019-02-13
BR112012004847B1 (pt) 2021-01-26
BR112012004847A2 (pt) 2016-11-16
AU2010291270A1 (en) 2012-03-15
EP2473599A1 (en) 2012-07-11
WO2011026882A1 (en) 2011-03-10
AU2010291270B2 (en) 2014-08-07
ZA201201387B (en) 2012-11-28

Similar Documents

Publication Publication Date Title
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
HRP20181422T1 (hr) Mdck-derivirane stanične linije prilagođene kulturi bez seruma i suspenzijskoj kulturi te postupak proizvodnje virusa cjepiva koristeći navedene stanice
HK1207828A1 (en) Cell-derived viral vaccines with low levels of residual cell dna dna
MX350274B (es) Vacunas para hsv-2.
MX2009012812A (es) Proteinas estructurales de una mutacion del parvovirus como vacunas.
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
MX346245B (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
CL2012000452A1 (es) Acido nucleico infeccioso de virus torque teno porcino (pttv), que comprende secuencia que codifica un pttv infeccioso con una secuencia genomica de pttv 1a-va; acido nucleico, plasmido y celula hospedera que la comprenden; pttv infeccioso no virulento; vacuna.
WO2011082388A3 (en) Infectious dna vaccines against chikungunya virus
WO2011106607A3 (en) Subunit vaccines for herpes viruses and methods of use
EP2576789A4 (en) INTENSE ATTENUATED LIVE VACCINES AND SUBUNITARY VACCINES CREATED BY RANDOM DNA RECOMBINATION ("DNA SHUFFLING") AGAINST PORCINE RESPIRATORY AND REPRODUCTIVE SYNDROME VIRUS (VSRRP)
NZ608143A (en) Recombinant modified vaccinia virus ankara (mva) influenza vaccine
CA2763359C (en) New human rotavirus strains and vaccines
MX350932B (es) Formulaciones virales liquidas.
MX349294B (es) Formulaciones virales liofilizadas.
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
PH12015501378A1 (en) Porcine parvovirus 5a, methods of use and vaccine
WO2011119716A3 (en) Flavivirus host range mutations and uses thereof
CO6670515A2 (es) Vectores de parapoxvirus
MX2012002702A (es) Vacuna de herpesvirus bovino.
MX2013000787A (es) Vectores de parapoxvirus.
EP2484376A4 (en) METHOD, KIT, PLASMID AND COMPOSITION FOR INDUCING AN IMMUNE RESPONSE AGAINST THE DENGUE VIRUS USING DNA VACCINES AND CHIMERIC VIRUSES
EP2593548A4 (en) ANTIGEN E7 COMPOSITIONS OF HUMAN PAPILLOMAVIRUS AND USES THEREOF
IN2015DN01342A (es)
EP2501405A4 (en) COMPOSITION, METHOD, AND USES OF POX VIRUS ELEMENTS IN VACCINATE CONSTRUCTS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal